Randomized Study to Characterize Glycemic Control and Short-term Pulmonary Function in Patients with Type 1 Diabetes Receiving Inhaled Human Insulin (Exubera).
From: University of California at San Francisco, Valley Research, Fresno, Ca 93720, USA. norwood@pol.net
The Journal of clinical endocrinology and metabolism
- Publish Date: Jun 2007
- ISSN: 0021-972X
- Volume: 92
- Issue: 6
- Pages: 2211-4
- Medium: Print
- Language: English
- Citation (JAMA): Norwood Paul, Dumas Richard, Cefalu William, et al. Randomized Study to Characterize Glycemic Control and Short-term Pulmonary Function in Patients with Type 1 Diabetes Receiving Inhaled Human Insulin (Exubera).. J. Clin. Endocrinol. Metab. Jun 2007;92:2211-4
Abstract
OBJECTIVE: Previous studies with inhaled human insulin [Exubera (EXU); insulin human (recombinant DNA origin) Inhalation Powder, Pfizer Inc., New York, NY; Nektar Therapeutics, San Carlos, CA) show comparable efficacy to sc insulin and small declines in pulmonary function in type 1 and 2 diabetes. This is a detailed characterization of short-term efficacy and pulmonary safety profile of EXU. RESEARCH DESIGN AND METHODS: In a 24-wk multicenter study, 226 nonsmoking patients with type 1 diabetes and normal lung function were randomized to intensive regimens of premeal EXU or sc insulin for 12 wk (comparative phase), followed by sc insulin for 12 wk (washout phase). Glycosylated hemoglobin, hypoglycemia, general adverse events, and pulmonary function were measured. Forced expiratory volume in 1 sec and carbon monoxide diffusion capacity were measured using standardized equipment and methodology. RESULTS: Comparable declines from baseline in glycosylated hemoglobin were observed in both groups (0.5%) and sustained throughout the study. There was a higher rate of hypoglycemia (risk ratio 1.23; 90% confidence interval 1.16, 1.30) but a lower rate of severe hypoglycemia (risk ratio 0.51; 90% confidence interval 0.30, 0.86) with EXU vs. sc insulin. The treatment group differences in changes from baseline in forced expiratory volume in 1 sec and carbon monoxide diffusion capacity were small, occurred within 2 wk of EXU initiation, and were reversible shortly after discontinuation. More patients reported mild cough with EXU vs. sc insulin (30.9% vs. 7.8%, respectively). CONCLUSIONS: Three months of EXU therapy is as effective and well tolerated as intensive sc insulin therapy. This study supports the role of EXU in type 1 diabetes.
Mesh Headings (Keywords): Administration, Inhalation, Adult, Aged, Blood Glucose, Cough, Diabetes Mellitus, Type 1, Hemoglobin A, Glycosylated, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Insulin, Lung, Middle Aged, Respiratory Function Tests, Treatment Outcome
Check for Full Text / PubMed Unique Identifier (PMID): 17003088
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.